The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The anti-neoplastic agents market has witnessed rapid growth, and this trend is expected to continue. The market size is projected to increase from $118.03 billion in 2023 to $130.01 billion in 2024, with a compound annual growth rate (CAGR) of 10.1%. In the forecast period, from 2023 to 2028, the market is anticipated to grow to $184.17 billion at a CAGR of 9.1%.

• Cancer Incidence on the Rise:
  • Anticipated increase in new cancer cases, reaching 1.9 million in the US in 2023.
  • Growing number of cancer-related deaths, with 609,820 expected in 2023.
• Role of Antineoplastic Agents:
  • Essential role in inhibiting cancer cell growth and division through various mechanisms.
  • Mechanisms include DNA damage, cell cycle disruption, and interference with crucial cellular pathways.
• Key Market Players:
  • Major companies driving the market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and others.
  • These companies play a vital role in meeting the increasing demand for anti-neoplastic treatments.

View More On The Anti-Neoplastic Agents Market Report 2023 – https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

Leading Companies Drive Antineoplastic Agent Market Through Clinical Advancements
Major players in the anti-neoplastic agents market are actively engaged in clinical advancements to maintain their market position. For instance, Novartis AG secured FDA approval for Pluvicto, a targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. This exemplifies the commitment of leading companies to advance cancer treatment through innovative therapies.

• Novartis Clinical Advancements:
  • FDA approval for Pluvicto targeting PSMA-positive metastatic castration-resistant prostate cancer.
  • Treatment regimen includes intravenous administration every six weeks for a maximum of six doses.
• Ipsen’s Strategic Acquisition:
  • In August 2022, Ipsen SA acquired Epizyme Inc. for $247 million, expanding its oncology portfolio.
  • Acquisition focused on Tazverik, a chemotherapy-free EZH2 inhibitor, enhancing Ipsen’s position in the anti-neoplastic market.

Ipsen Expands Oncology Portfolio With Acquisition Of Epizyme Inc
In a strategic move, Ipsen SA, a France-based biopharmaceutical company, acquired Epizyme Inc. for $247 million in August 2022. This acquisition aimed to bolster Ipsen’s oncology portfolio, particularly with the addition of Tazverik, a first-in-class chemotherapy-free EZH2 inhibitor. Epizyme Inc., a US-based biopharmaceutical company specializing in anti-neoplastic agents, contributed significantly to Ipsen’s expansion in the oncology sector.

• Strategic Acquisition Highlights:
  • Ipsen’s acquisition of Epizyme Inc. for $247 million.
  • Focus on expanding oncology portfolio through Tazverik, an EZH2 inhibitor.

Market Segmentation and Regional Dynamics
The anti-neoplastic agents market is segmented based on type, disease type, and end-user categories. This segmentation provides a comprehensive understanding of the market landscape, catering to various aspects of cancer treatment.

• Market Segmentation:
  • Types include Alkylating Agents, Antimetabolites, Hormones and Antagonists, and Miscellaneous.
  • Disease types cover Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, and Other Disease Types.
  • End users encompass Hospitals, Clinics, Cancer Rehabilitation Centers, and Ambulatory Surgical Centers.
• Regional Dynamics:
  • North America emerged as the largest region in the anti-neoplastic agents market in 2023.
  • Asia-Pacific is poised to be the fastest-growing region in the forecast period, indicating the global nature of the market’s expansion.

Request A Sample Of The Global Anti-Neoplastic Agents Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12901&type=smp

The Anti-Neoplastic Agents Global Market Report 2023  provides a comprehensive overview on the anti-neoplastic agents market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Soft Tissue Repair Global Market Report 2023
Orthopedic Soft Tissue Repair Global Market Report 2023
Tissue Diagnostic Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model